Long-term spatiotemporal variations of atmospheric sulfur, nitrogen and particle pollutants in Chongqing, southwest China: implication of industrial transfer

Abstract

Industrial transfer has swept through in China. However, there is still a knowledge gap about its environmental effects. In this study, industrial transfer status was assessed and evaluated by industrial ratios (%; the gross product contributions of the secondary industry to the whole industry) and the impact of such transfer on atmospheric environment (SO₂, NO₂, PM₁₀ (particles with aerodynamic diameter less than 10 μm), precipitations of SO₄²⁻, NO₃⁻, and NH₄⁺) in the 38 districts and counties in Chongqing was analyzed and discussed for the period of 2006–2015. Results showed that industries were transferred obviously from the main urban region (MUR) into the 1-h economic region (OHER). Atmospheric sulfur and PM₁₀ were efficiently put in control, but atmospheric nitrogen (NO₂; precipitations of NO₃⁻ and NH₄⁺) was increasing and posted a potential threat to air quality especially during 2011–2015. Correlations showed that industrial ratios had significantly positive relationships with concentrations of ambient SO₂ and PM₁₀ in the MUR and ambient NO₂ in the OHER (p < 0.05) while a remarkably negative one with concentrations of ambient SO₂ in the OHER (p < 0.05) during 2006–2015, implying that industrial transfer could be effective in transferring sulfur pollution but not as efficient in transferring atmospheric nitrogen and PM₁₀ pollutions as SO₂ between in the MUR and OHER. More measures should be taken to reduce nitrogen and PM₁₀ emission and a regional monitoring network of ambient NH₃ is in urgent need.

from Energy Ecology Environment Ambio via Terpsi Hori on Inoreader http://bit.ly/2G2LR1z

Development of biodegradable coatings for maize seeds and their application for Azospirillum brasilense immobilization

Abstract

The objective of this study was to develop biodegradable coatings for agriculture crop seeds based on starch, gelatin, and polyvinyl alcohol (PVA). Developed materials were characterized according to their microstructures, barrier properties, influence on germination of maize seeds, and ability to sustain Azospirillum brasilense Ab-V5 viability in coated maize seeds. The coatings were obtained employing different proportions of starch, gelatin, and PVA, ranging from 0 to 3.0 g/100 g of each material, respectively. Samples formulated with the pure polymers showed the highest values of water absorption capacity, solubility, and water vapor permeability, and the ternary mixtures showed the lowest values. Single polymer formulations and the binary starch-gelatin mixture (CS50GL50) favored maize seeds germination compared to the uncoated maize seeds. In addition, seed coating obtained from CS50GL50 formulation resulted in A. brasilense Ab-V5 viability in coated seeds up to 15 days after bacterial immobilization, being considered a promising low-cost, biodegradable, and renewable source material to be used in agriculture.

from A via a.sfakia on Inoreader http://bit.ly/2B8Luzn

Comparative analysis of two non-specific nucleases of the phospholipase D family from the plant pathogen competitor bacterium Pantoea agglomerans

Abstract

Bacterial non-specific nucleases of the phospholipase D family are widely distributed among the members of the Enterobacteriaceae. Each genome mainly contains a single copy of a gene encoding a phospholipase D family protein. However, two distantly related isozymes (< 40% identity at the protein level) were identified by BLAST-analyses in the plant pathogenic competitor enterobacterium Pantoea agglomerans. The two nucleases PaNuc-1 and PaNuc-2 were produced in Escherichia coli. Identical gene constructs and expression conditions resulted in the production of PaNuc-1 in soluble form, while PaNuc-2 remained insoluble in inclusion bodies. PaNuc-2 was refolded and both proteins were purified by a combination of affinity and ion exchange chromatography. Proteolytic removal of the HIS-tag allowed the characterization of pure and mature tag-less proteins. Enzymatic properties of both isozymes revealed that they are non-specific nucleases, displaying activities against RNA, single- and double-stranded genomic DNA as well as circular plasmids. However, their biochemical activity profiles were clearly different, with PaNuc-1 being optimally active at 70 °C and pH 7.0, while PaNuc-2 was most active at 45 °C and pH 7.0. The enzymes retained > 90% nuclease activity at EDTA concentrations of 4 mM (PaNuc-2) and 20 mM (PaNuc-1), respectively. Different enzymatic properties suggest that the roles of PaNuc-1 and PaNuc-2 differ in the cell and might be the result of functional diversification after an ancient gene duplication event took place. The fact that both enzymes could be easily produced in recombinant form and their tolerance against metal ion chelators in combination with a broad substrate promiscuity might pave the way to versatile biotechnological applications.

from A via a.sfakia on Inoreader http://bit.ly/2Tib5Nd

Bovine colostrum-driven modulation of intestinal epithelial cells for increased commensal colonisation

Abstract

Nutritional intake may influence the intestinal epithelial glycome and in turn the available attachment sites for bacteria. In this study, we tested the hypothesis that bovine colostrum may influence the intestinal cell surface and in turn the attachment of commensal organisms. Human HT-29 intestinal cells were exposed to a bovine colostrum fraction (BCF) rich in free oligosaccharides. The adherence of several commensal bacteria, comprising mainly bifidobacteria, to the intestinal cells was significantly enhanced (up to 52-fold) for all strains tested which spanned species that are found across the human lifespan. Importantly, the changes to the HT-29 cell surface did not support enhanced adhesion of the enteric pathogens tested. The gene expression profile of the HT-29 cells following treatment with the BCF was evaluated by microarray analysis. Many so called "glyco-genes" (glycosyltransferases and genes involved in the complex biosynthetic pathways of glycans) were found to be differentially regulated suggesting modulation of the enzymatic addition of sugars to glycoconjugate proteins. The microarray data was further validated by means of real-time PCR. The current findings provide an insight into how commensal microorganisms colonise the human gut and highlight the potential of colostrum and milk components as functional ingredients that can potentially increase commensal numbers in individuals with lower counts of health-promoting bacteria.

from A via a.sfakia on Inoreader http://bit.ly/2B4x2Zo

Immobilization of cellulase in the non-natural ionic liquid environments to enhance cellulase activity and functional stability

Abstract

Ionic liquids (ILs) have been applied as an environmentally friendly solvent in the pretreatment of lignocellulosic biomass for more than a decade. The ILs involved pretreatment processes for cellulases mediated saccharification lead to both the breakdown of cellulose crystallinity and the decrease of lignin content, thereby improving the solubility of cellulose and the accessibility of cellulase. However, most cellulases are partially or completely inactivated in the presence of even low amount of ILs. Immobilized cellulases are found to perform improved stability and higher apparent activity in practical application compared with its free counterparts. Enzyme immobilization therefore has become a promising way to relieve the deactivation of cellulase in ILs. Various immobilization carriers and methods have been developed and achieved satisfactory results in improving the stability, activity, and recycling of cellulases in IL pretreatment systems. This review aims to provide detailed introduction of immobilization methods and carrier materials of cellulase, including natural polysaccharides, synthetic polymers, inorganic materials, magnetic materials, and newly developed composite materials, and illustrate key methodologies in improving the performance of cellulase in the presence of ILs. Especially, novel materials and concepts from the recently representative researches are focused and discussed comprehensively, and future trends in immobilization of cellulases in non-natural ILs environments are speculated in the end.

from A via a.sfakia on Inoreader http://bit.ly/2sLoBgR

Agronomic and environmental factors affecting cultivation of the winter mushroom or Enokitake: achievements and prospects

Abstract

The global interest in production of the winter mushroom or Enokitake (Flammulina filiformis previously known as Flammulina velutipes) is increasing owing to its nutritional and medicinally important bioactive compounds along with a marketable texture and flavor. This review presents the state of knowledge on achievements in solid-state cultivation and submerged cultures of Enokitake and how they are influenced by environmental factors and agronomic characteristics. A wide range of basic lignocellulosic substrates and supplementations have been reviewed in order to formulate an efficient and locally available substrate. Domestication of wild types of Enokitake and its economic and research implications are also discussed. Besides, the influence of environmental and agronomic factors on production and efficacy of the most important biologically active metabolites of Enokitake in both solid-state cultivation and submerged cultures has been discussed. Some of shortcomings of studies reporting cultivation of Enokitake are described and their contribution to future prospects is also discussed in this review.

from A via a.sfakia on Inoreader http://bit.ly/2sLYmHf

Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma

Publication date: March 2019

Source: Neoplasia, Volume 21, Issue 3

Author(s): Peter Dietrich, Anne Gaza, Laura Wormser, Valerie Fritz, Claus Hellerbrand, Anja Katrin Bosserhoff

Abstract

Inhibition of the RAS-RAF-ERK-pathway using sorafenib as a first-line and regorafenib as a second-line treatment approach is the only effective therapeutic strategy for advanced hepatocellular carcinoma (HCC). Recent studies suggest that wild-type KRAS and HRAS isoforms could majorly contribute to HCC progression and sorafenib resistance. In contrast, the role of neuroblastoma RAS viral oncogene homolog (NRAS) in HCC remained elusive. In this study, wild-type NRAS was found to be overexpressed in HCC cell lines, preclinical HCC models, and human HCC tissues. Moreover, NRAS overexpression correlated with poor survival and proliferation in vivo. However, si-RNA-pool–mediated NRAS knockdown showed only slight effects on HCC proliferation, clonogenicity, and AKT activity. We determined that KRAS upregulation served as a functional compensatory mechanism in the absence of NRAS, which was overcome by combined inhibition of NRAS and KRAS in HCC cells. Furthermore, NRAS expression was elevated in sorafenib-resistant compared to nonresistant HCC cells, and NRAS knockdown enhanced sorafenib efficacy in resistant cells. In summary, NRAS appears to be a prognostic marker in HCC and contributes to sorafenib resistance. Regarding potential therapeutic strategies, NRAS inhibition in HCC should be combined with KRAS inhibition to prevent KRAS-mediated rescue effects.

from A via a.sfakia on Inoreader http://bit.ly/2UcUQkG

A new immunoassay of hybrid nanomater conjugated to aptamers for the detection of dengue virus

Publication date: 15 May 2019

Source: Talanta, Volume 197

Author(s): Caroline R. Basso, Bruno P. Crulhas, Massimiliano Magro, Fabio Vianello, Valber A. Pedrosa

Abstract

A new immunosensor using hybrid nanomaterials for the detection of dengue virus was demonstrated in this work. This immunosensor composed of nanoparticles of γ-Fe₂O₃(SAMN) modified with MPA- SAMN@MPA was characterized by FTIR spectroscopy, transmission electron microscopy,quartz crystal microbalance, UV–vis and LSPR technique. The binding of SAMN@MPA with AuNPs conjugated with aptamers(SAMN@MPA@AuNPs@aptamer) provides specific chemical bonds to four dengue serotypes. Colorimetric changes in the modification steps provided rapid visual detection of the virus without the use of equipment. Variations of aptamers concentrations 1.0-10.0 μM where the 3.0 μM aptamer concentration is sufficient to completely cover the surface of the modified AuNPs with an R² value of> 0.99. This new proposed methodology presenting some advantages in relation to traditional detection methods such as time optimization and cost,can be used as a diagnostic method.

Graphical abstract

The colorimetric tests show SAMNs (A), AuNPs (B), SAMNs@MPA@AuNPs@aptamer complex (C), after addition of the DENV pool (D), interference test with ZIKV (E) and YFD (F).

from A via a.sfakia on Inoreader http://bit.ly/2WlpMkA

Environmentally friendly etching of stainless steel wire for plunger-in-needle liquid-phase microextraction of polycyclic aromatic hydrocarbons

Publication date: 15 May 2019

Source: Talanta, Volume 197

Author(s): Piyaluk Nurerk, Christina Shu Min Liew, Opas Bunkoed, Proespichaya Kanatharana, Hian Kee Lee

Abstract

An environmentally friendly method of etching a stainless steel plunger wire, to replace the conventional hydrofluoric acid approach, was developed for plunger-in-needle liquid phase-microextraction (PIN-LPME). The one-step etching procedure was performed by immersing the plunger wire in a ferric chloride-hydrochloric acid (FeCl₃-HCl) solution. The etched wire was then used for LPME as the organic solvent holder. After solvent coating, the wire was directly exposed to a water sample for extraction of polycyclic aromatic hydrocarbons (PAHs), which were then subjected to thermal desorption in the injector of a gas chromatograph for gas chromatography-mass spectrometric (GC-MS) analysis. The parameters affecting PIN-LPME efficiencies (i.e., extraction solvent, solvent coating mode and time, stirring rate, extraction time and salting effect) were also investigated. Under the most favourable conditions, PIN-LPME-GC-MS exhibited high enrichment factors of between 70 and 349 for the 9 PAHs, low detection limits (between 0.006 and 0.058 ng mL⁻¹), and good precision (with relative standard deviations ranging from 4.4% to 9.7%). The developed method was successfully applied for the extraction and determination of PAHs in tap, river and drain water samples. Good relative recoveries of the PAHs over the range of 84.3–101.9% were obtained with spiked genuine water samples.

Graphical abstract

from A via a.sfakia on Inoreader http://bit.ly/2RgsPqG

A combined targeted/untargeted LC-MS/MS-based screening approach for mammalian cell lines treated with ionic liquids: Toxicity correlates with metabolic profile

Publication date: 15 May 2019

Source: Talanta, Volume 197

Author(s): Corinna Sanwald, Alexandra Robciuc, Suvi-Katriina Ruokonen, Susanne K. Wiedmer, Michael Lämmerhofer

Abstract

This work presents the development and validation of a quantitative HILIC UHPLC-ESI-QTOF-MS/MS method for amino acids combined with untargeted metabolic profiling of human corneal epithelial (HCE) cells after treatment with ionic liquids. The work included a preliminary metabotoxicity screening of 14 different ionic liquids, of which 9 carefully selected ionic liquids were chosen for a metabolomics study. This study is focused on the correlation between the toxicity of the ionic liquids and their metabolic profiles. The method development included the comparison of different MS/MS acquisition modes. A sequential window acquisition of all theoretical fragment ion mass spectra (SWATH) method with variable Q1 window widths and narrow Q1 target windows of 5 Da for most of the amino acids was selected as the optimal acquisition mode. Due to the absence of a true blank matrix, ¹³C,¹⁵N-isotopically labelled amino acids were utilized as surrogate calibrants, instead of proteinogenic amino acids. Partial least squares (PLS) analysis of the median effective concentrations (EC₅₀) of 9 selected ionic liquids showed a correlation with their metabolic profile measured by the untargeted screening.

Graphical abstract

from A via a.sfakia on Inoreader http://bit.ly/2Wi5kkG

Intracerebral injection of R-(-)-Apomorphine into the nucleus accumbens decreased carbachol-induced 22-kHz ultrasonic vocalizations in rats

Publication date: Available online 26 January 2019

Source: Behavioural Brain Research

Author(s): Michael Silkstone, Stefan M. Brudzynski

Abstract

Rats can produce ultrasonic vocalizations (USVs) in a variety of different contexts that signal their emotional state to conspecifics. Under distress, rats can emit 22-kHz USVs, while during positive pro-social interactions rats can emit frequency-modulated (FM) 50-kHz USVs. It has been previously reported that rats with increasing emission of FM 50-kHz USVs in anticipation of rewarding electrical stimulation or positive pro-social interaction decrease the number of emitted 22-kHz USVs. The purpose of the present investigation was to determine, in a pharmacological-behavioural experiment, if the positive emotional arousal of the rat indexed by the number of emitted FM 50-kHz USVs can decrease the magnitude of a subsequent negative emotional state indexed by the emission of 22-kHz USVs. To induce the positive emotional arousal, an intracerebral injection of a known D₁/D₂ agonist R-(-)-apomorphine (3.0 µg/0.3 µl) into the medial nucleus accumbens shell was used, while the negative emotional arousal was induced by intracerebral injection of carbachol (1.0 µg/0.3 µl), a known broad-spectrum muscarinic agonist, into the anterior hypothalamic-medial preoptic area. Our results demonstrated that initiation of a positive emotional state was able to significantly decrease the magnitude of subsequently expressed negative emotional state measured by the number of emitted 22-kHz USVs. The results suggest the neurobiological substrates that initiate positive emotional state antagonize the brain regions that initiate negative emotional states.

from A via a.sfakia on Inoreader http://bit.ly/2TbdERq

Anorexia increases microglial density and cytokine expression in the hippocampus of young female rats

Publication date: Available online 25 January 2019

Source: Behavioural Brain Research

Author(s): Durairaj Ragu Varman, Mayra Macedo-Mendoza, Francisco Emmanuel Labrada-Moncada, Pamela Reyes-Ortega, Teresa Morales, Ataúlfo Martínez-Torres, Daniel Reyes-Haro

Abstract

Anorexia by osmotic dehydration is an adaptive response to hypernatremia and hyperosmolaemia induced by ingestion of a hypertonic solution. Dehydration-induced anorexia (DIA) reproduces weight loss and avoidance of food, despite its availability. By using this model, we previously showed increased reactive astrocyte density in the rat dorsal hippocampus, suggesting a pro-inflammatory environment where microglia may play an important role. However, whether such anorexic condition increases a pro-inflammatory response is unknown. The aim of this study was to test if DIA increases microglial density in the dorsal hippocampus, as well as the expression of pro-inflammatory cytokines tumor necrosis alpha (TNF-α), interleukin 6 (IL-6) and interleukin 1 beta (IL-1β) in the hippocampus of young female rats. Our results showed that DIA significantly increased microglial density in CA2-CA3 and dentate gyrus (DG) but not in CA1. However, forced food restriction (FFR) only increased microglial density in the DG. Accordingly, the activated/resting microglia ratio was significantly increased in CA2-CA3 and DG, in DIA and FFR groups. Finally, western blot analysis showed increased expression of IBA1, TNF-α, IL-6 and IL-1β in the hippocampus of both experimental groups. We conclude that anorexia triggers increased reactive microglial density and expression of TNF-α, IL-6 and IL-1β; this environment may result in hippocampal neuroinflammation.

from A via a.sfakia on Inoreader http://bit.ly/2B7vTA3

Sex differences in the progressive model of parkinsonism induced by reserpine in rats

Publication date: Available online 25 January 2019

Source: Behavioural Brain Research

Author(s): José M.M. Bispo, João E.C. Melo, Auderlan M. Gois, Pollyana C. Leal, Lívia C.R.F. Lins, Marina F. Souza, Katty A.A.L. Medeiros, Alessandra M. Ribeiro, Regina H. Silva, Murilo Marchioro, José R. Santos

ABSTRACT

Parkinson's disease (PD) exhibits sexual differences in susceptibility and pathogenesis in humans, with a high incidence in men and a high severity of motor symptoms in male rodents. Furthermore, studies showed that the administration of low dose of reserpine (RES) induces a progressive appearance of motor alterations similar with parkinsonism in male rodents. Here, we investigated sex differences in motor deficits and tyrosine hydroxylase (TH) immunoreactivity induced by a progressive model of parkinsonism. Gonadally intact male and female Wistar rats and ovariectomized female rats received 15 subcutaneous injections (s.c.) every other day of 0.1 mg / kg of RES or vehicle. The repeated administration of low doses of RES (0.1 mg/kg) produces sexually dimorphic impairments on motor performance (catalepsy and open field test). Intact and ovariectomized females were more resistant to the deleterious effect of repeated administration of reserpine in the early, but this resistance in intact female disappears over time. However, intact females showed a reduction of the TH immunoreactivity in substantia nigra pars compacta, but not in ventral tegmental area and dorsal striatum. These results suggest a possible application of this model in the study of sexual dimorphism throughout the progression of PD.

from A via a.sfakia on Inoreader http://bit.ly/2ThxTwz

Tissue sodium concentration and sodium T1 mapping of the human brain at 3 T using a Variable Flip Angle method

Publication date: Available online 26 January 2019

Source: Magnetic Resonance Imaging

Author(s): Arthur Coste, Fawzi Boumezbeur, Alexandre Vignaud, Guillaume Madelin, Kathrin Reetz, Denis Le Bihan, Cécile Rabrait-Lerman, Sandro Romanzetti

Abstract

Purpose

The state-of-the-art method to quantify sodium concentrations in vivo consists in a fully relaxed 3D spin-density (SD) weighted acquisition. Nevertheless, most sodium MRI clinical studies use short-TR SD acquisitions to reduce acquisition durations. We present a clinically viable implementation of the Variable Flip Angle (VFA) method for robust and clinically viable quantification of total sodium concentration (TSC) and longitudinal relaxation rates in vivo in human brain at 3 T.

Methods

Two non-Cartesian steady-state spoiled ultrashort echo time (UTE) scans, performed at optimized flip angles, repetition time and pulse length determined under specific absorption rate constraints, are used to simultaneously compute T₁ and total sodium concentration (TSC) maps using the VFA method. Images are reconstructed using the non-uniform Fast Fourier Transform algorithm and TSC maps are corrected for possible inhomogeneity of coil transmission and reception profiles. Fractioned acquisitions are used to correct for potential patient motion. TSC quantifications obtained using the VFA method are validated at first in comparison with a fully-relaxed SD acquisition in a calibration phantom. The robustness of similar VFA acquisitions are compared to the short-TR SD approach in vivo on seven healthy volunteers.

Results

The VFA method resulted in consistent TSC and T₁ estimates across our cohort of healthy subjects, with mean TSC of 38.1 ± 5.0 mmol/L and T₁ of 39.2 ± 4.4 ms. These results are in agreement with previously reported values in literature TSC estimations and with the predictions of a 2-compartment model. However, the short-TR SD acquisition systematically underestimated the sodium concentration with a mean TSC of 31 ± 4.5 mmol/L.

Conclusion

The VFA method can be applied successfully to image sodium at 3 T in about 20 min and provides robust and intrinsically T₁-corrected TSC maps.

from A via a.sfakia on Inoreader http://bit.ly/2FOFKig

Eigenvector-based SPIRiT Parallel MR Imaging Reconstruction based on ℓp pseudo-norm Joint Total Variation

Publication date: Available online 25 January 2019

Source: Magnetic Resonance Imaging

Author(s): Jizhong Duan, Zhongwen Bao, Yu Liu

Abstract

Parallel Magnetic Resonance (MR) imaging is a well-established acceleration technique based on the spatial sensitivities of array receivers. Eigenvector-based SPIRiT (ESPIRiT) is a new parallel MR imaging reconstruction method that combines the advantages of the SENSE and GRAPPA methods. It estimates multiple sets of the sensitivity maps from the calibration matrix that is constructed from the auto-calibration data. To improve the quality of the reconstructed image, we introduced the Total Variation (TV) and ℓ_p pseudo-norm Joint TV (ℓ_pJTV) regularization terms to the ESPIRiT model for parallel MR imaging reconstruction, which were solved by using the Operator Splitting (OS) method. The resulting denoising problems with the TV and ℓ_pJTV regularization terms were solved by exploiting the majorization minimization method. Simulation experiments on two in vivo data sets demonstrated that the proposed OS algorithm with the TV regularization term (OSTV) and OS algorithm with the ℓ_pJTV regularization term (OSℓ_pJTV) outperformed the conventional method with the ℓ₁ regularization term in terms of SNR and NRMSE. And the OSℓ_pJTV algorithm was slightly superior to the OSTV algorithm with the TV regularization term.

from A via a.sfakia on Inoreader http://bit.ly/2G3Eln5

Sonophotocatalytic treatment of rhodamine B using visible-light-driven CeO 2 /Ag 2 CrO 4 composite in a batch mode based on ribbon-like CeO 2 nanofibers via electrospinning

Abstract

CeO₂/Ag₂CrO₄ composite photocatalyst was successfully fabricated using electrospinning and calcination and chemical precipitation method based on CeO₂ ribbon-like fibers and characterized by field-emission scanning electron microscopy (FESEM), energy dispersive X-ray (EDX), X-ray diffraction (XRD), UV–Vis diffuse reflectance spectroscopy (DRS) and Fourier-transform infrared spectroscopy (FT-IR). The as-obtained CeO₂/Ag₂CrO₄ composite used photocatalytic performance in the sonophotodegradation of rhodamine B in aqueous solution under visible-light (LED) irradiation. DRS analysis illustrates that CeO₂/Ag₂CrO₄ composite exhibited enhanced absorption in the visible region-attributed CeO₂ nanofibers_. The effect of four effective parameters including initial concentration of rhodamine B (RhB), photocatalyst dosage, pH, and irradiation time was studied and optimized using central composite design. The kinetic studies confirmed ability of pseudo first-order reaction based on the Langmuir–Hinshelwood model for fitting empirical data, while its rate constant (k_obs), L–H rate constants (k_r), and L–H adsorption constants (K_A) were 0.0449 min⁻¹, 11.66 mg L⁻¹ min⁻¹ and 1.09E−3 mg L⁻¹, respectively. The enhanced photocatalytic activity could be ascribed to the ultrasound field and formation of a heterojunction system among CeO₂ and Ag₂CrO₄, which lead to a better mass transfer and higher efficiency of charge electron–hole separation, respectively.

from Energy Ecology Environment Ambio via Terpsi Hori on Inoreader http://bit.ly/2B5hBA5

Chironomid genera distribution related to environmental characteristics of a highly impacted basin (Argentina, South America)

Abstract

The objective of the present study was to investigate the responses of the chironomid communities (Diptera: Chironomidae) to environmental variables in four moderately and highly disturbed rivers located in one of the most degraded watersheds in South America. Sampling campaigns were carried out during 2014–2016 in four sites of the Matanza-Riachuelo basin. The physical-chemical and hydrological variables were measured and, the ecological indices were calculated and evaluated by ANOVA. The responses of Chironomidae to the environmental variables were evaluated by redundancy analysis (RDA), and the sampling sites were grouped according to the populations of chironomids and the main environmental variables. Finally, the Spearman correlation was made to determine which of these variables were significant. In total, 13 chironomid taxa were found in 36 samples during the study period. The greatest density registered belongs to Rheotanytarsus and Cricotopus. The ANOVA detected the greatest Chironomidae density and taxonomic richness in the sites with agricultural-urban impact. The changes in the distribution of Rheotanytarsus, Thienemanniella, and Polypedilum were mainly explained by the increase in current velocity, organic matter, and hardness, and the decrease of NH3 and BOD. On the other hand, Goeldichironomus, Chironomus, Parachironomus, Dicrotendipes, and Cricotopus were explained by the increase in conductivity, dissolved oxygen, and temperature, and the decrease of the variables NO3, BOD, and Cu. In addition to this, the sites with urban-agricultural impact were clearly separated from sites with urban-industrial impact. The last one was more related to the increase in BOD, Cu, and NO3 that indicates moderate to poor water quality. In conclusion, we can infer that the physical and chemical variables are correlated with changes in the structure and distribution of the chironomid community and there are genera that respond differently at high and intermediate situations of disturbances. This knowledge contributes to the execution of strategies for the conservation and restoration of the lotic ecosystems.

from Energy Ecology Environment Ambio via Terpsi Hori on Inoreader http://bit.ly/2Tgy1fY

Effects of fertilizer type and rate on summer maize grain yield and ammonia volatilization loss in northern China

Abstract

Purpose

In this study, we analyzed the effects of different maize varieties with nitrogen utilization efficiency, fertilizer type, and rate on the ammonia volatilization emission of farmland. Aimed to seek the best matching method to improve grain yield and fertilizer utilization efficiency of summer maize simultaneously.

Materials and methods

In field experiments, we choose two maize varieties with different nitrogen utilization efficiency (Zhengdan958, Z and Lainong14, L) as material. Set four different fertilizer treatments (200 kg N hm⁻² inorganic fertilizer (U1), 100 kg N hm⁻² inorganic fertilizer (U2), 200 kg N hm⁻² organic fertilizer (M1), and 100 kg N hm⁻² organic fertilizer (M2) to study their effect on NH₃ emission and loss, maize grain yield, and nitrogen accumulation.

Results and discussion

Ammonia volatilization accounted for 8.61–21.68% of applied N. Under the same variety, ammonia volatilization accumulation after fertilization was as follows: U1 > U2 > M1 > M2. Ammonia volatilization rates increased first and then gradually decreased after the fertilization. The ammonia volatilization loss and cumulative loss increased due to increased nitrogen fertilizer application rate. The average nitrogen accumulation and harvest index of 200 kg N hm⁻² N treatments were higher than 100 kg N hm⁻² N treatments, and the difference between the inorganic fertilizer and organic fertilizer was not significant. In 2016 and 2017, the average yield of Zhengdan958 was 11,758.79 kg hm⁻², which was 15.78% higher than that of Lainong14, and the difference between the two fertilizer types was not significant. The average yield of 200 kg N hm⁻² N treatment was 11,959.42 kg hm⁻², which was 20.13% higher than those of 100 kg N hm⁻² N treatment.

Conclusions

By changing the type of fertilizer, replacing chemical fertilizers with organic fertilizer can reduce the loss of ammonia volatilization and promote the synergistic improvement to yield and resource utilization efficiency. Among them, using nitrogen-efficient varieties and using organic fertilizer instead of chemical fertilizer was beneficial to reduce the loss of ammonia volatilization, increase the accumulation of nitrogen, and promote the growth of maize to obtain high yield.

from Energy Ecology Environment Ambio via Terpsi Hori on Inoreader http://bit.ly/2MDwcaw

The role of unilateral nasal inspiratory peak flow in nasal obstruction‐ a study of seventy patients undergoing septorhinoplasty surgery

Abstract

Nasal Inspiratory Peak Flow (NIPF) poorly correlates with subjective patient reported outcomes (PROMs) following functional septorhinoplasty.

The aim of this study is to determine whether unilateral NIPF correlates with PROMs.

The study demonstrates significant improvement in objective and subjective measurements post septorhinoplasty surgery in seventy patients.

There was weak correlation between improvements in bilateral NIPF when compared with changes in the NOSE score.

Whilst unilateral NIPF does not correlate with subjective outcome scores, it is still a useful measure in assessing nasal patency and in patient education.

This article is protected by copyright. All rights reserved.

from A via a.sfakia on Inoreader http://bit.ly/2DzijY3

Association study of cell cycle proteins and human papillomavirus in laryngeal cancer in Chinese Population

Abstract

Objective

To investigate the role of human papillomavirus (HPV) in laryngeal squamous cell carcinoma (LSCC) and analyze the relationship between HPV and the expression of cell cycle‐related proteins.

Design

The study consisted of LSCC between 2005 and 2011 in Tongren Hospital. Clinical data such as age, sex, smoking/ alcohol consumption and TNM stage were collected. HPV DNA and cell cycle‐related proteins were assessed in terms of clinical features.

Setting

Single center study.

Participants

A total of 332 LSCC patients were included in the study.

Main outcome measures

The presence of genotype‐specific HPV DNA was evaluated using PCR‐RDB in formalin‐fixed paraffin‐embedded tissues. All samples were also evaluated for p16^INK4A, p21^WAF1/CIP1, P53, Cyclin D1, and Ki67 immunohistochemical staining by tissue microarray.

Results

HPV DNA was detected in 45 of 332 (13.55%) patients with LSCC, with HPV‐16 being the predominant genotype. The presence of HPV‐16 DNA was significantly associated with basaloid squamous cell carcinoma and cystic lymph node metastasis (P < 0.05). Of the 332 patients 36 (10.84%) were scored as p16^INK4A positivity, and they were more likely to be female (P < 0.05). Cyclin D1‐positivity and p21^WAF1/CIP1‐positivity were observed in 60.24% (200/332)and 40.66%(135/332), respectively. In 114 cases (34.33%), LSCCs had moderate‐ to ‐strong p53 accumulation, which was correlated with TNM stage (P < 0.05). HPV‐16 DNA was correlated with p16^INK4A, and manifested a higher Ki‐67 labeling index and p21^WAF1/CIP1 expression than HPV‐16‐negative tumors (P < 0.05). No relationship was observed between Cyclin D1or P53 expression and HPV‐16 infection (P > 0.05).

Conclusion

HPV DNA was detected in 13.55% patients with LSCC, with HPV‐16 being the predominant genotype and it was correlated with p16^INK4A, and manifested a higher Ki‐67 labeling index and p21^WAF1/CIP1 expression than HPV‐16‐negative tumors.

This article is protected by copyright. All rights reserved.

from A via a.sfakia on Inoreader http://bit.ly/2UiMSqa

Infectious complications following heart transplantation in the era of high-priority allocation and extracorporeal membrane oxygenation

Infectious complications are a major cause of morbidity and mortality after heart transplantation (HT). However, the epidemiology and outcomes of these infections in the recent population of adult heart transp...

from A via a.sfakia on Inoreader http://bit.ly/2RhsbsS

Evaluation and optimization of a methodology for the long-term cryogenic storage of Tetradesmus obliquus at − 80 °C

Abstract

Cryopreservation is a common methodology for long-term microalgae storage. Current cryopreservation methods are based on using diverse cryoprotectants and two-step cooling protocols, followed by sample storage at the temperature of liquid nitrogen (− 196 °C). However, the use of this methodology requires a continuous liquid N₂ supply as well as facilities with dedicated equipment, which is not affordable for every laboratory. In our work, we report on the successful development of a simple and cost-effective method for the long-term cryogenic storage of Tetradesmus obliquus at temperatures (− 80 °C) used in commonly available deep freezers that are more readily accessible to laboratories. Two procedures were evaluated that were originally devised for other microalgae; this was followed by the optimization of critical parameters such as the sample's microalgal concentration and the cryoprotectant reagent's incubation time. Cell viability was monitored using the survival rates obtained by direct agar plating and the growth recovery times in liquid cultures. Viability-related variables were recorded following different storage times of up to 3 years. The main operational factors involved in the process (cell concentration, incubation time, and storage time) were statistically analyzed with regard to their influence on the survival rate. The statistical analysis showed interdependence (a two-factor interaction) between the cellular concentration and the cryoprotectant's incubation time, on the one hand, and between the incubation time and the storage time on the other. Survival rates above 70% were obtained under optimized conditions after 3 months of storage, along with 20–35% viabilities after 3 years. These results open up the possibility of extending this method to other Scenedesmaceae, or even other microalgal species, and for its use in resource-limited laboratories.

from A via a.sfakia on Inoreader http://bit.ly/2Uhh595

Modeling the effect of the cephalic phase of insulin secretion on glucose metabolism

Abstract

The nervous system has a significant impact in glucose homeostasis and endocrine pancreatic secretion in humans, especially during the cephalic phase of insulin release (CPIR); that is, before a meal is absorbed. However, the underlying mechanisms of this neural-pancreatic interaction are not well understood and therefore often neglected, despite their significance to achieving an optimal glucose control. As a result, the dynamics of insulin release from the pancreas are currently described by mathematical models that reproduce the behavior of the β cells using exclusively glucose levels and other hormones as inputs. To bridge this gap, we have combined, for the first time, metabolic and neural mathematical models in a unified system to reproduce to a great extent the ideal glucoregulation observed in healthy subjects. Our results satisfactorily replicate the CPIR and its impact during the post-absorptive phase. Furthermore, the proposed model gives insight into the physiological interaction between the brain and the pancreas in healthy people and suggests the potential of considering the neural information for restoring glucose control in people with diabetes.

Graphical Abstract

(a) Physiological scenario. Diagram of the biological interaction among the most important organs involved in glucose control during meal intake. (b) Scheme of the unified bio-inspired neural-metabolic model. Each of the boxes represents one subsystem of the model. The pink shades boxes depicts the novel subsystems introduced to the current metabolic models (grey shaded boxes). Insulin-related action and mass fluxes (solid black lines) and glucose-related action and mass flux (dotted black lines) are depicted to show the relationship among the blocks. I(t), I_c(t), G(t) and SI related to plasma insulin, plasma cephalic insulin, plasma glucose and insulin sensitivity, respectively.

from A via a.sfakia on Inoreader http://bit.ly/2DzhzSG

Exact inter-discharge interval distribution of motor unit firing patterns with gamma model

Abstract

Inter-discharge interval distribution modeling of the motor unit firing pattern plays an important role in electromyographic decomposition and the statistical analysis of firing patterns. When modeling firing patterns obtained from automatic procedures, false positives and false negatives can be taken into account to enhance performance in estimating firing pattern statistics. Available models of this type, however, are only approximate and use Gaussian distributions, which are not strictly suitable for modeling renewal point processes. In this paper, the theory of point processes is used to derive an exact solution to the distribution when a gamma distribution is used to model the physiological firing pattern. Besides being exact, the solution provides a way to model the skewness of the inter-discharge distribution, and this may make it possible to obtain a better fit with available experimental data. In order to demonstrate potential applications of the model, we use it to obtain a maximum likelihood estimator of firing pattern statistics. Our tests found this estimator to be reliable over a wide range of firing conditions, whether dealing with real or simulated firing patterns, the proposed solution had better agreement than other models.

Graphical Abstract

Model of the MU firing pattern generation and detection: f_T,1(τ), IDI PDF of the physiological firing pattern; f_T(τ), IDI PDF after modeling undetected firings (false negatives); f_S(τ), IDI PDF after modeling classification errors (false positives)

from A via a.sfakia on Inoreader http://bit.ly/2CMsnv7

Self‐Assembled Gels formed in Deep Eutectic Solvents – Supramolecular Eutectogels with High Ionic Conductivities

This paper reports the ability of 1,3:2,4‐dibenzylidene‐D‐ sorbitol (DBS), a simple, commercially‐relevant compound, to self‐assemble as a result of intermolecular non‐covalent interactions into supramolecular gels in deep eutectic solvents (DESs). The DESs are based on choline chloride combined with alcohols/ureas – DBS forms gels at a loading of 5% wt/vol. Rheology confirms the gel‐like nature of the materials, electron microscopy indicates underpinning nanofibrillar DBS networks and differential scanning calorimetry shows the deep eutectic solvent nature of the liquid‐like phase is retained. The ionic conductivities of the gels are similar to those of the unmodified DESs proving the deep eutectic nature of the ionic liquid‐like phase. Gelation is tolerant of ionic additives Li+, Mg2+ and Ca2+, with the resulting gels having similar conductivities to electrolyte dissolved in the native DES. The low‐molecular‐weight gelator DBS is a low‐cost additive – forming gels in DESs from readily‐available constituents, with conductivity levels suitable for practical applications. We suggest supramolecular eutectogels have potential uses ranging from energy technology to synthesis and catalysis.

from A via a.sfakia on Inoreader http://bit.ly/2S6KGF2

Active oxygen enhanced homogeneous nucleation of Li‐metal on ultrathin layered double hydroxide

The development of safe lithium (Li)‐metal anode is crucial for the next‐generation rechargeable batteries. To stabilize Li metal anode, preplanting Li nucleation seeds on lithiophilic substrates is an efficient strategy to regulate initial nucleation process of Li‐metal. Herein, we first reported the activated ultrathin layered double hydroxide (U‐LDHs) as a promising lithiophilic 2D material to realize the uniform deposition of Li metal. The experimental studies and DFT calculations reveal that the active oxygen on U‐LDHs provides abundent atomic‐scale active sites for Li homogeneous nucleation and plating. Moreover, the lithiophilic property of active oxygen is also related to its coordination environments. This work opens up an opportunity to more accurate regulation and understanding of Li nucleation from atomic‐scale based on 2D ultrathin materials.

from A via a.sfakia on Inoreader http://bit.ly/2HvRbgA

A Photoresponsive Stiff‐Stilbene Ligand Fuels the Reversible Conformational Unfolding of G‐Quadruplex DNA

The polymorphic nature of G‐quadruplex (G4) DNA structures points to a range of potential applications in nanodevices and an opportunity to control G4 in biological settings. Light is an attractive means for the regulation of oligonucleotide structure as it can be delivered with high spatiotemporal precision. However, surprisingly little attention has been devoted towards the development of ligands for G4 that allow photoregulation of G4 folding. We report a novel G4‐binding chemotype derived from stiff‐stilbene. Surprisingly however, whilst the ligand induces high stabilization in the potassium form of human telomeric DNA, it causes the unfolding of the same G4 sequence in sodium buffer. This effect can be reversed on‐demand by irradiation with 400 nm light through deactivation of the ligand by photo‐oxidation. By fueling the system with the photolabile ligand, the conformation of G4 DNA was switched five times.

from A via a.sfakia on Inoreader http://bit.ly/2Hxkmzz

Promoting the Outgrowth of Neurites on Electrospun Microfibers by Functionalization with Electrosprayed Microparticles of Fatty Acids

Controlling the outgrowth of neurites is important for enhancing the repair of injured nerves and understanding the development of nervous systems. Here we report a simple strategy for enhancing the outgrowth of neurites through a unique integration of topographical guidance and chemical cue. We use electrospray to easily functionalize the surface of a substrate with microparticles of natural fatty acids at a controllable density. Through a synergistic effect from the surface roughness arising from the microparticles and the chemical cue offered by the fatty acids, the outgrowth of neurites from PC12 cells is greatly enhanced. We also functionalize the surfaces of uniaxially aligned, electrospun microfibers with the microparticles and further demonstrate that the substrates can guide and enhance directional outgrowth of neurites from both PC12 multicellular spheroids and chick embryonic dorsal root ganglia bodies. On the aligned microfibers decorated with an optimal density of the microparticles, the outgrowth of neurites is maximized. This work offers a simple and practical system to design substrates for controlling neurite outgrowth, holding promise for applications in enhancing neural tissue regeneration and understanding neuronal development.

from A via a.sfakia on Inoreader http://bit.ly/2S7s07T

The cyclic phosphoramidite reagent c‐PyPA enables iterative polyphosphorylations

An iterative polyphosphorylation approach is described, which is based on a phosphoramidite (P‐amidite) derived reagent (c‐PyPA) obtained from the cyclization of pyrophosphate with a reactive diisopropylamino dichlorophosphine. This type of reagent is unprecedented as it represents a reactive P‐amidite without protecting groups. The reagent proved to be stable in solution over several weeks. Its utility is described in the context of iterative monodirectional and bidirectional polyphosphorylations. The ensuing functionalized cyclotriphosphate can be opened with a variety of nucleophiles providing ready access to diverse functionalized polyphosphate chains of defined length with several tags, including both P‐N and P‐O labels. Their interaction with exo‐ and endopolyphosphatases is described.

from A via a.sfakia on Inoreader http://bit.ly/2HAjPNm

Ni‐Catalyzed Asymmetric Reductive Diarylation of Vinylarenes

A Ni‐catalyzed asymmetric diarylation reaction of vinylarenes represents a compelling method for preparing chiral α,α,β‐triarylated ethane scaffolds, which exist in a number of biologically active molecules. The use of reducing conditions with aryl bromides as coupling partners avoids stoichiometric organometallic reagents and tolerates a broad range of functional groups. The application of an N‐oxyl radical as a ligand to Ni catalysts represents a novel approach to facilitate Ni‐catalyzed cross‐coupling reactions.

from A via a.sfakia on Inoreader http://bit.ly/2SaTt8W

Predicting the limit of intramolecular H‐Bonding with classical molecular dynamics

The energetics of intramolecular recognition processes are governed by the balance of pre‐organization and flexibility that is often difficult to measure and hard to predict. Here, by using state‐of‐the‐art classical molecular dynamics simulations, we predict and quantify the effective strength of intramolecular interactions between H‐bond donor and acceptor sites separated by a variable alkyl linker—in a variety of solvents and including crowded solutions. The fine balance of entropic and enthalpic contributions posits a solvent‐dependent limit to the occurrence of intramolecular H‐bonding. Nevertheless, H‐bond free energies are rigidly shifted among different solvents with, for example, a systematic ~13 kJ/mol gap between water and chloroform. Molecular crowding shows little effects on thermodynamic equilibrium but it induces pronounced variations on H‐bond kinetics. The results are in quantitative agreement with available experimental measurement (in chloroform) and showcase a general strategy to interrogate molecular interactions in different environments, extending the limits of current experiments towards the prospective prediction of H‐bond interactions in pharmaceutical, agrochemical, and technological contexts.

from A via a.sfakia on Inoreader http://bit.ly/2HwN0B5

Isolation and Synthesis of Novel Meroterpenoids from Rhodomyrtus tomentosa: Investigation of a Reactive Enetrione Intermediate

Rhodomyrtusials A–C (5–7), the first examples of triketone‐sesquiterpene meroterpenoids featuring a unique 6/5/5/9/4 fused pentacyclic ring system were isolated from Rhodomyrtus tomentosa, along with several biogenetically‐related dihydropyran isomers (8–11). Compounds 5, 6, and 10 showed acetylcholinesterase (AChE) inhibitory activity. Structures of the isolates were unambiguously established by a combination of spectroscopic data, ECD analysis, and total synthesis. Bioinspired total syntheses of 5, 7, and 8–11 were achieved in six steps utilizing a reactive enetrione intermediate generated in situ from a readily available hydroxy‐endoperoxide precursor.

from A via a.sfakia on Inoreader http://bit.ly/2Hxh5jP

Ethanol‐Precipitable, Silica‐Passivated Perovskite Nanocrystals Incorporated into Polystyrene Microspheres for Long‐Term Storage and Reusage

A new method for preparing silica‐passivated perovskite nanocrystals that are precipitable by polar solvents without destroying their surface chemistry or losing quantum yield, and can also be encapsulated into non‐crosslinked polystyrene microspheres for long‐term storage against moisture and reusage.

Abstract

Perovskite nanocrystals (PNCs) are emerging luminescent materials due to their fascinating physic‐optical properties. However, their sensitive surface chemistry with organic polar solvents, oxygen, and moisture greatly hinders their developments towards practical applications. Herein we promote silica‐passivated PNCs (SP‐PNCs) by in situ hydrolyzing the surface ligands of (3‐aminopropyl) triethoxysilane. The resultant SP‐PNCs possesses a high quantum yield (QY) of 80 % and are precipitable by polar solvents, such as ethanol and acetone, without destroying their surface chemistry or losing QY, which offers an eco‐friendly and efficient method for separation, purification, and phase transfer of PNCs. Moreover, we further promoted a swelling–deswelling encapsulation process to incorporate the as‐made SP‐PNCs into non‐crosslinked polystyrene microspheres (PMs), which can largely increase the stability of the SP‐PNCs against moisture for long‐term storage.

from A via a.sfakia on Inoreader http://bit.ly/2CptGjc

Organophosphorus‐Catalyzed Deoxygenation of Sulfonyl Chlorides: Electrophilic (Fluoroalkyl)sulfenylation by PIII/PV=O Redox Cycling

Oat field: A method for electrophilic sulfenylation by organophosphorus‐catalyzed deoxygenative O‐atom transfer (OAT) from sulfonyl chlorides is reported. This C−S bond‐forming reaction is catalyzed by 1 (phosphetane) in conjunction with a hydrosilane terminal reductant to afford sulfenyl electrophiles, including valuable trifluoromethyl, perfluoroalkyl, and heteroaryl derivatives.

Abstract

A method for electrophilic sulfenylation by organophosphorus‐catalyzed deoxygenative O‐atom transfer from sulfonyl chlorides is reported. This C−S bond‐forming reaction is catalyzed by a readily available small‐ring phosphine (phosphetane) in conjunction with a hydrosilane terminal reductant to afford a general entry to sulfenyl electrophiles, including valuable trifluoromethyl, perfluoroalkyl, and heteroaryl derivatives that are otherwise difficult to access. Mechanistic investigations indicate that the twofold deoxygenation of the sulfonyl substrate proceeds by the intervention of an off‐cycle resting state thiophosphonium ion. The catalytic method represents an operationally simple protocol using a stable phosphine oxide as a precatalyst and exhibits broad functional‐group tolerance.

from A via a.sfakia on Inoreader http://bit.ly/2FpWBa4

From Lead Iodide to a Radical Form Lead‐Iodide Superlattice: High Conductance Gain and Broader Band for Photoconductive Response

Lead the way: The first lead‐iodide superlattice constructed from non‐ionic organic molecules and PbI₂ through van der Waals interactions is a new type of inorganic–organic hybrid and has a radical and a non‐radical form. The radical form has an almost five orders of magnitude greater conductivity and broader band photoconductive response than that of the non‐radical form or pure PbI₂.

Abstract

Superlattice materials offer new opportunities to modify optical and electrical properties of recently emerging 2D materials. The insertion of tetraethylbenzidine (EtDAB) into interlamination of the established 2D PbI₂ semiconductor through a mild solution method yielded the first lead iodide superlattice, EtDAB⋅4PbI₂ (EtDAB=tetraethylbenzidine), with radical and non‐radical forms. The non‐radical form has a non‐ionic structure that differs from the common ionic structures for inorganic–organic hybrid lead halides. The radical form shows five orders of magnitude greater conductance and broader photoconductive response range (UV/Vis → UV/Vis‐IR), than pure PbI₂ and the non‐radical form of the superlattice.

from A via a.sfakia on Inoreader http://bit.ly/2SGBWlQ

Polybismuthide Anions as Ligands: The Homoleptic Complex [(Bi7)Cd(Bi7)]4− and the Ternary Cluster [(Bi6)Zn3(TlBi5)]4−

A coordination compound with intact Bi₇³⁻ ligands, namely the homoleptic complex [(Bi₇)Cd(Bi₇)]⁴⁻, and the ternary cluster [(Bi₆)Zn₃(TlBi₅)]⁴⁻ were prepared through in situ degradation of the binary Zintl anion (TlBi₃)²⁻. The compounds provide a glimpse into a possible formation pathway of the polycyclic polybismuthide, the follow‐up chemistry of which has been unprecedented to date. Both title compounds were further studied by means of DFT methods.

Abstract

We present the results from a reactivity study of the binary anion (TlBi₃)²⁻ towards Group 12 metal compounds MPh₂ (M=Zn, Cd, Hg) to gain access to coordination compounds of polycyclic polypnictide molecules such as Bi₇³⁻ or Bi₁₁³⁻. The coordination chemistry of these polybismuthide cages has been unprecedented to date, while it has been known for a long time for the lighter Group 15 anions Pn₇³⁻ (Pn=P, As, Sb). The use of (TlBi₃)²⁻, previously shown to release Tl under certain conditions in situ, resulted in the formation of the first heterometallic polyanion in which a nortricyclane‐type polybismuthide coordinates a transition‐metal atom, [(Bi₇)Cd(Bi₇)]⁴⁻. Reactions with the lighter Group 12 metal precursor yielded the uncommon ternary cluster [(Bi₆)Zn₃(TlBi₅)]⁴⁻, most likely representing a reaction intermediate, and at the same time hinting at the formation of the nortricyclane‐shaped cage. Quantum‐chemical studies provide deeper insight into the stability trends of the [(E₇)M(E₇)]⁴⁻ anion family and reveal a complex bonding situation in [(Bi₆)Zn₃(TlBi₅)]⁴⁻, which features both localized and multi‐center bonding.

from A via a.sfakia on Inoreader http://bit.ly/2C135ZR

Grand Prix de la Fondation de la Maison de la Chimie/And also in the News

from A via a.sfakia on Inoreader http://bit.ly/2S7mQZx

Photoredox‐Catalyzed Cyclobutane Synthesis via a Deboronative Radical Addition–Polar Cyclization Cascade

Photoredox‐catalyzed methylcyclobutanations of alkylboronic esters are described. The reactions proceed via single‐electron transfer induced deboronative radical addition to an electron‐deficient alkene followed by single‐electron reduction and polar 4‐exo‐tet cyclization with a pendant alkyl halide. Key to the success of the methodology was the use of easily oxidizable arylboronate complexes. Structurally diverse cyclobutanes are shown to be conveniently prepared from readily available alkylboronic esters and a range of haloalkyl alkenes. The mild reactions display excellent functional group tolerance, and the radical addition–polar cyclization cascade also enables the synthesis of 3‐, 5‐, 6‐, and 7‐membered rings.

from A via a.sfakia on Inoreader http://bit.ly/2HyRebm

A Stable Lithium–Oxygen Battery Electrolyte Based on Fully Methylated Cyclic Ether

Full methyl jacket: A fully methylated cyclic ether 4,4,5,5‐hexamethyl‐1,3‐dioxolane is used as an electrolyte solvent for Li–O₂ batteries. It exhibits excellent stability in the presence of superoxide or singlet oxygen because all the active α‐H atoms are substituted with methyl groups. The cycling performance is 4 times greater that of conventional ether electrolytes.

Abstract

Ether‐based electrolytes are commonly used in Li–O₂ batteries (LOBs) because of their relatively high stability. But they are still prone to be attacked by superoxides or singlet oxygen via hydrogen abstract reactions, which leads to performance decaying during long‐term operation. Herein we propose a methylated cyclic ether, 2,2,4,4,5,5‐hexamethyl‐1,3‐dioxolane (HMD), as a stable electrolyte solvent for LOBs. Such a compound does not contain any hydrogen atoms on the alpha‐carbon of the ether, and thus avoids hydrogen abstraction reactions. As the result, this solvent exhibits excellent stability with the presence of superoxide or singlet oxygen. In addition the CO₂ evolution during charge process is prohibited. The LOB with HMD‐based electrolyte was able to run up to 157 cycles, 4 times more than with 1,3‐dioxolane (DOL) or 1,2‐dimethoxyethane (DME) based electrolytes.

from A via a.sfakia on Inoreader http://bit.ly/2Al1yO0

Clinical Trials News

Mon Jan 07, 2019 00:00

Clinical Trials Survey

Would you like to help improve the clinical research experience for patients? We are interested in your opinion about reporting your symptoms for clinical trials. Please click the link below to complete this short, 5-minute survey. Your anonymous responses will be used for research purposes to better understand how to improve patient care. Complete the survey and provide your email address to be entered to win a $100 Visa gift card! Thank you for taking the time to provide your opinion.

ClinicalConnection.com New Clinical Trials

Mon Jan 07, 2019 00:00

Schizophrenia - Princeton NJ

Do you or a loved one suffer from Schizophrenia? If so, Princeton Medical Institute located in Princeton, NJ is conducting a clinical research trial of an investigational treatment for Schizophrenia. We're seeking volunteers 18 to 65 years old who have been diagnosed with Schizophrenia Study-related exams, procedures, and medication are provided at no cost. Visit our website to learn more and submit your interest! Common Symptoms of Schizophrenia May Include: Withdrawal from reality Hallucinations...

ClinicalConnection.com New Clinical Trials

Sun Jan 06, 2019 00:00

Pediatric Plaque Psoriasis - Clearwater FL

Click image to enlargeLocal dermatologists are conducting a clinical research study to test the effectiveness and safety of an investigational topical medication for Plaque Psoriasis.Qualified Participants Must:Be 12-16 years old Provide consent and be accompanied by a legal guardian at the time of consent signing Have an Investigator's Global Assessment (IGA) score of at least 3 Be willing to comply with all study instructions and commit to follow-up visits Females must not be pregnant and agree...

ClinicalConnection.com New Clinical Trials

Fri Jan 04, 2019 00:00

<b>Eczema (Atopic Dermatitis) - Webster TX</b>

Click image to enlarge

ClinicalConnection.com New Clinical Trials

Thu Jan 03, 2019 00:00

<b>ADHD with Impulsive Aggression - Grand Prairie TX</b>

 Aggression refers to a behavior that can result in both physical and psychological harm to oneself, others or objects in the environment. Aggression is manifested verbally, mentally, and physically. Such behavior becomes maladaptive when it persists, occurs outside an acceptable social context, and is of an intensity, frequency, severity and/or duration detrimental to the child's interests. This is a double-blind, randomized, parallel group, two-arm, placebo-controlled study with flexible dosing...

ClinicalConnection.com New Clinical Trials

Thu Jan 03, 2019 00:00

Osteoarthritis of the Knee - La Mesa CA

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Woodstock GA

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Excessive Underarm Sweating Study for Children - Raleigh NC

Does Your Child Struggle with Excessive Underarm Sweat?Consider Joining a Clinical Research Study of a New MedicationWake Research is enrolling participants in a study of an investigational medication for excessive underarm sweat in children and teens.

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Phoenix AZ

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Remove ads

Osteoarthritis of the Knee - Albuquerque NM

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Kansas City MO

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Carmichael CA

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Edgewater FL

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - San Angelo TX

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Charleston SC

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

<b>Osteoarthritis of the Knee - Multiple Locations in the US</b>

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Cincinnati OH

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Alzheimer's Disease - Spring Hill FL

If you are caring for someone with Alzheimer's disease, please consider the ROAD clinical research study, which will determine the safety and effectiveness of the multifunctional small moleculeAD-35 in patients with mild to moderate Alzheimer's disease (AD).Key Eligibility Criteria• Between 50 and 85 years of age (inclusive)• Diagnosed with probable AD in accordance with the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria• Mini-Mental State Examination (MMSE) score of ≥>...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Child ADHD - Lakeland FL

Is your child is experiencing the following symptoms:  trouble staying focused, interrupts others, hyper or impulsive or does not listen, OR has already been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD)? If yes, learn more about a medical research study evaluating an investigational study drug in children 6 to 17 years of age. 

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Data Highlighting Potential Benefits of Lm Platform Presented at 2019 Keystone Symposia Conference on Cancer Vaccines

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that two presentations highlighting the potential of Advaxis vectors to generate T cell responses to a large percentage of neoantigens and to promote antigen spreading and potentially slow progression of prostate cancer, were presented at the 2019 Keystone Symposia on Cancer Vaccines, held January 19-24

Business Wire Health: Clinical Trials News

Fri Jan 25, 2019 15:05

Global PD-1 and PD-L1 Inhibitors Market 2019-2023 | Strong Pipeline to Boost Growth | Technavio

LONDON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Inhibitors?src=hash" target="_blank"gt;#Inhibitorslt;/agt;--The global PD-1 and PD-L1 Inhibitors market is expected to post a CAGR of over 19% during the period 2019-2023, according to Technavio.

Business Wire Health: Clinical Trials News

Fri Jan 25, 2019 14:00

Circassia to buy US, China marketing rights to AIT's AirNOvent

The acquired rights will cover all potential indications in the hospital setting for the administration of inhaled AirNOvent at up to 80 parts per million. One of the The post Circassia to buy US, China marketing rights to AIT's AirNOvent appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 08:54

Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression

NV-5138 is a first-in-class, orally-active small molecule that directly activates mTORC1, the gatekeeper of cellular metabolism and renewal, which is suppressed in the brain of people suffering from The post Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 08:54

FDA accepts X-Rx's IND application for X-165 to treat IPF

X-165 is a highly potent and selective small molecule inhibitor of Autotaxin owned by X-Rx. An initial advanced lead series that led to the identification of X-165 was The post FDA accepts X-Rx's IND application for X-165 to treat IPF appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 08:54

EC approves Clovis' Rubraca to treat women with relapsed ovarian cancer

The second indication of Rubraca has been approved as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer The post EC approves Clovis' Rubraca to treat women with relapsed ovarian cancer appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 06:56

ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 8, 2019 to discuss its 2018 operating results. Management will also provide a brief update on the business. Conference Call InformationTo access the live call by phone, dial 323-794-2093; the conference ID is 6271602. The call may also be a

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 23:30

Immunomic to Present at the 2019 BIO CEO & Investor Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that its' founder and CEO, William Hearl, Ph.D., will present an overview of the company and its UNITE technology platform at the 2019 BIO CEO & Investor Conference on February 12, 2019 at 2:00 pm EST in the Hudson/Empire Room at the Marriott Marquis in New York City. About UNITE ITI's investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Assoc

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 23:05

Vermont Collaborative Partners with Netsmart to Alter Trajectory of Care for State's Most Vulnerable

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Four member agencies of Vermont Care Partners (VCP) have come together to reshape the delivery and coordination of care through a partnership with Netsmart to deploy a unified technology platform. As value-based care quickly becomes reality, Lamoille County Mental Health Services, Northwestern Counseling and Support Services, United Counseling Services of Bennington and Washington County Mental Health Services will leverage the full suite of solutions from

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 22:00

Remove ads

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study

The treatment of patients with Bing-Neel syndrome (BNS) is not standardized. We included patients with Waldenström macroglobulinemia (WM) and a radiologic and/or cytologic diagnosis of BNS treated with ibrutinib monotherapy. Response assessment was based on criteria for BNS from the 8th International Workshop for WM. Survival from BNS diagnosis (BNS survival), survival from ibrutinib initiation to last follow-up or death (ibrutinib survival), and time from ibrutinib initiation to ibrutinib discontinuation...

Blood CLINICAL TRIALS AND OBSERVATIONS

Thu Jan 24, 2019 19:00

Oyster Point Pharma to Present at the BIO CEO & Investor Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Oyster Point Pharma to present a corporate overview at the BIO CEO & Investor Conference.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 17:33

Midwest Vision Research Foundation at Pepose Vision Institute Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts

ST. LOUIS, Mo.--(BUSINESS WIRE)--Midwest Vision Research Foundation at Pepose Vision Institute joins the AcuFocus IC-8® Lens clinical study for cataracts.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 16:05

Tamr Joins Accenture's Life Sciences Ecosystem to Help Drive Innovation in Drug Discovery and Scientific Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tamr Inc. today announced it has joined Accenture's open partner ecosystem, designed to help independent software vendors (ISVs) and life science companies team more effectively to accelerate drug discovery efforts and improve patient outcomes. The ecosystem is an integral part of Accenture's cloud-based informatics research platform, which has been designed to help life sciences organizations improve productivity, efficiency, and innovation in drug discovery.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 16:00

Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting

BOSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell announces data from NAM-NK and NiCord® programs to be presented at 2019 TCT Annual Meeting

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 15:32

X-Rx Announces FDA Acceptance of IND Application for X-165

WALTHAM, Mass.--(BUSINESS WIRE)--X-Rx Announces FDA Acceptance of IND Application for X-165

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 15:15

Can-Fite BioPharma CEO Letter to Shareholders

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that Pnina Fishman, Chief Executive Officer of Can-Fite Biopharma, has issued a Letter to Shareholders, the full text of which follows below. Dear Can-Fite Shareholders, It has been a very busy and productive year at Can Fite BioPharma, filled with c

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:30

Dicerna Evolves Its Board of Directors to Support Continued Growth

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna announced several changes to its board of directors, reflecting the company's ongoing growth.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:30

Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer

BURLINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ARQL&src=ctag" target="_blank"gt;$ARQLlt;/agt; lt;a href="https://twitter.com/hashtag/arql?src=hash" target="_blank"gt;#arqllt;/agt;--ArQule, Inc.'s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche's PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®),...

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00

Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/CNCE?src=hash" target="_blank"gt;#CNCElt;/agt;--Concert began a Phase 1 single-ascending dose trial to evaluate the safety, tolerability, and PK profile of CTP 692 in healthy volunteers.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00

Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Ohio Supreme Court has dismissed a Petition filed by Capital Royalty Partners II, L.P. and affiliated entities. On August 27, 2018, Capital Royalty Partners II, L.P. and several affiliated entities ("CRG") filed a Petition with the Ohio Supreme Court seeking a

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00

Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results

NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank"gt;$BMYlt;/agt;--Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 13:59

BridgeBio Pharma raises $299.2m in financing round

BridgeBio Pharma will also use the funds to expand its efforts on the development of medicines for patients with unmet needs. Both existing investors KKR and Viking Global The post BridgeBio Pharma raises $299.2m in financing round appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Thu Jan 24, 2019 13:17

Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463

Data from the Phase 1 study are expected in the second half of 2019. "The initiation of this Phase 1 study with IW-6463 marks an important milestone for The post Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463 appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Thu Jan 24, 2019 11:20

BioNTech to acquire MAB Discovery's antibody generation unit

Under the terms of the agreement, BioNTech will acquire all assets, employees and proprietary know-how for mAb generation from MAB Discovery. MAB Discovery will retain ownership of and The post BioNTech to acquire MAB Discovery's antibody generation unit appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Thu Jan 24, 2019 13:17

ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorisation (CMA) Application for ANCA-Associated Vasculitis in Europe, Phase III Advocate Trial Data Release Planned for Q4 2019

ZURICH & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Regulatory News: ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd., a company of Vifor Pharma Group, today announced that in light of the upcoming availability of data from the pivotal Phase III ADVOCATE trial – the largest controlled trial in active anti-neutrophil cytoplasmic antibody associated vasculitis (ANCA-associated vasculitis) – they have decided to withdraw the application for Conditional Marketing Authorisation (CM

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 08:00

Gossamer Bio Announces Commencement of Initial Public Offering

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") in connection with the commencement of a proposed initial public offering of its common stock. Gossamer Bio is offering 14,375,000 sha

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 00:24

Advaxis' Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced receipt of notification from the U.S. Food and Drug Administration (FDA) that the Company's ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac (AXAL) in high-risk, locally advanced cervical cancer (AIM2CERV) has been placed on partial clinical

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 23:05

Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders. Data from the Phase 1 study are expected in the second half of 2019. "The initiation of this Phase 1 study with IW-6463 marks an im

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 23:01

Vedanta Biosciences Announces Publication in Nature of Seminal Research Revealing A New Mechanism of Human Microbiota-Driven Antitumor Immunity Involving Induction of IFNy+ CD8+ T Cell Accumulation in the Gut and Tumors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences announced a publication in Nature that revealed a newly discovered mechanism underlying antitumor immunity.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 20:07

Remove ads

Modulated Imaging Raises $7M in Series B Funding

IRVINE, Calif.--(BUSINESS WIRE)--Modulated Imaging has raised $7 million in Series B funding to fund the commercialization of its Clarifi technology and clinical studies.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 19:30

Vascular Dynamics Names Prof. Martin Rothman Chief Medical Officer

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--World-renowned interventional cardiologist Martin Rothman has been named chief medical officer at VDI.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 19:05

Redx gets regulatory nod to restart RXC004 clinical trial

An oral porcupine inhibitor, RXC004 has been designed to target the Wnt signaling pathway. The early-stage trial of the small molecule drug was temporarily stopped in March 2018 The post Redx gets regulatory nod to restart RXC004 clinical trial appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 17:43

U.S. Patent Office Issues CEL-SCI Two Patents for Its LEAPS Vaccine Platform Technology

VIENNA, Va.--(BUSINESS WIRE)--U.S. patent office issues CEL-SCI two patents for its LEAPS vaccine platform technology.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 16:20

Medidata Joins the World Economic Forum

NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MDSO?src=hash" target="_blank"gt;#MDSOlt;/agt;--Medidata (NASDAQ:MDSO) today announced that it has entered into a three-year strategic collaboration with the World Economic Forum. The company becomes a Partner Member Associate and will participate in the WEF System Initiative focused on Shaping the Future of Health and Healthcare. The initiative has a goal of transforming the continuum of care – from prevention to diagnosis, treatment,...

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:30

Ferring Pharmaceuticals appoints Sophie Opdyke to lead its new U.S. oncology division

PARSIPPANY, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Ferring?src=hash" target="_blank"gt;#Ferringlt;/agt;--Sophie Opdyke, Pharm.D., MBA, will be responsible for building the Ferring Pharmaceuticals (U.S.) oncology division

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:25

InGeneron Expands Development Pipeline with Two Osteoarthritis Programs

HOUSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/backpain?src=hash" target="_blank"gt;#backpainlt;/agt;--InGeneron expands development pipeline with two studies for chronic backpain and wrist osteoarthritis, setting focus on orthopedic indications.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:00

BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source

PALO ALTO, Calif.--(BUSINESS WIRE)--BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR and Viking Global Investors. Other existing investors participating included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Hercules Capital; and they were joined by new investors Sequoia Capital, and a blue-chip long-term investor. The financing wil

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:00

Talee Bio Announces $4.5 Million Award from the Cystic Fibrosis Foundation to Advance Development of Two Gene Therapy Product Candidates

PHILADELPHIA--(BUSINESS WIRE)--Talee Bio, Inc., a development stage biopharmaceutical company focused on developing gene therapy treatments for cystic fibrosis, today announced agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL-101 and TL-102. The CF Foundation committed up to $4.5 million to expedite the development of both product candidates for all people with cystic fibrosis, and par

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski, Ph.D., to the company's board of directors. "We are extremely pleased to add these two experienced executives to Sage's board of directors. As Sage continues to advance its programs in development, adding an executive

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

Triumvira Announces Build out of Senior Management Team with Addition of Industry-Experienced Professionals in R&D and Business Development

AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira appoints Andreas Bader as Senior Vice President of Research & Development and Joshua Carle as Vice President of Business Development.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model

LOS ANGELES--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Breastfeeding?src=hash" target="_blank"gt;#Breastfeedinglt;/agt;--Supplementation with unique B3 vitamin nicotinamide riboside confers significant and enduring physiological benefits to mouse mothers and offspring.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 13:30

Idiopathic Pulmonary Fibrosis Report - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Idiopathic Pulmonary Fibrosis . The report includes information of marketed products including their product des

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 13:24

EC approves Blincyto in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor ALL

The approval was based on data from the Phase 2 BLAST study in frontline and relapsed/refractory ALL, the largest prospective trial for MRD-positive ALL ever conducted. BLINCYTO, a The post EC approves Blincyto in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor ALL appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 11:52

Rocket Pharmaceuticals announces clearance of IND for RP-A501 gene therapy for Danon disease

RP-A501 is the Company's first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of The post Rocket Pharmaceuticals announces clearance of IND for RP-A501 gene therapy for Danon disease appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 11:52

GSK closes acquisition of Tesaro for $5.1bn

Tesaro acquisition will enable GSK to strengthen its pharmaceutical business; and expand its pipeline and commercial capability in oncology. Tesaro president and COO Dr Mary Lynne Hedley said: The post GSK closes acquisition of Tesaro for $5.1bn appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 11:52

UroGen Pharma Announces Proposed Public Offering of Ordinary Shares

NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of ordinary shares sold in the offering at the pu

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 23:01

LabCorp Named to FORTUNE Magazine's 2019 List of 'World's Most Admired Companies,' Making the Annual List for the Second Consecutive Year

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine's 2019 List of World's Most Admired Companies, making the annual list for the second consecutive year. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, is given to top executives, directors, and financial analysts to identify the companies that enjoy the strongest reputations within their indust

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 17:35

Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration

BOSTON & MINNEAPOLIS--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell and Be The Match BioTherapies® announced a collaboration to improve outcomes for patients undergoing bone marrow transplantation.

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:30

Bio-Thera Solutions Announces Initiation of Phase III Clinical Trial for BAT1806, a Proposed Biosimilar of Actemra® (Tocilizumab)

GUANGZHOU, China--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/arthritis?src=hash" target="_blank"gt;#arthritislt;/agt;--Bio-Thera Solutions announces the initiation of a Phase III clinical trial for BAT1806, a proposed biosimilar of Actemra® (Tocilizumab).

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:08

Remove ads

LabConnect Announces Global Sample Processing Network

SEATTLE--(BUSINESS WIRE)--LabConnect is pleased to announce a new service: LabConnect's global sample processing network (GSPN).

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, February 7, 20191:30 p.m. Pacific Time / 4

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Rainier Therapeutics Announces Oral Abstract Presentation on Fierce 21 Phase 2 Trial of Vofatamab in Metastatic Urothelial Cell Carcinoma (Bladder Cancer) at the 2019 ASCO Genitourinary Cancers Symposium

SAN LEANDRO, Calif.--(BUSINESS WIRE)--Data from ongoing P2 trial of Rainier's FGFR3-targeted antibody vofatamab to be presented at 2019 ASCO Genitourinary Cancers Symposium Feb 14 in SF

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Resumen: Gore presenta en Europa la endoprótesis para aorta torácica adaptable GORE® TAG® con perfiles reducidos

FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) ha introducido hoy perfiles reducidos para los diámetros más utilizados de la endoprótesis para aorta torácica adaptable GORE® TAG® con el sistema de CONTROL ACTIVO. El perfil reducido permite a los médicos realizar reparaciones endovasculares torácicas (TEVAR) en pacientes con vasos más pequeños donde el acceso es difícil y la anatomía aórtica es tortuosa, lo que amplía la disponibilidad de la endoprótesis para aorta

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:47

Samenvatting: Gore introduceert GORE® TAG® Conformable Thoracic Stent Graft met gereduceerde profielen in Europa

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) introduceerde vandaag gereduceerde profielen voor de meest gebruikte diameters van de GORE® TAG® Conformable Thoracic Stent Graft met ACTIVE CONTROL System. Het gereduceerde profiel stelt artsen in staat om TEVAR uit te voeren bij patiënten met kleinere vaten waar de toegang moeilijk is en de aorta anatomie kronkelig is, waardoor de beschikbaarheid van Gore's thoracale stenttransplantaat wordt uitgebreid naar een groter

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:47

Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

WILMINGTON, Del.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24INCY&src=ctag" target="_blank"gt;$INCYlt;/agt;--Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:30

Data Presented at LINC Confirm the Safety and Effectiveness of Zilver® PTX®

BLOOMINGTON, Ind.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/cookmedical?src=hash" target="_blank"gt;#cookmedicallt;/agt;--Today at the Leipzig Interventional Course (LINC), Cook Medical participated in significant discussion about the use of paclitaxel to treat patients suffering from PAD. Through several presentations to meeting attendees, data supported the use of paclitaxel-coated devices to help the more than 200 million1 patients globally who are fighting the disease. "We believe...

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:10

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2 head-to-head study evaluating the efficacy, safety and tolerability of voclosporin ophthalmic solution (VOS 0.2%) versus Restasis®(cyclosporine ophthalmic emulsion 0.05%) for the treatment of dry eye syndrome (DES). Both drugs were shown to be well-tolerate

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/AlopeciaAreata?src=hash" target="_blank"gt;#AlopeciaAreatalt;/agt;--Concert completed enrollment in its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata.

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Immunochina Raises $20.4 Million USD in Series C Financing

BEIJING--(BUSINESS WIRE)--Beijing-based Immunochina Pharmaceuticals today announced the closing of its $140 million RMB Series C financing (approximately $20.4 million in US Dollars). This financing will enable the company to expand its GMP-grade manufacturing capabilities while continuing clinical trials for its lead IM19 product targeting B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Non Hodgkin's Lymphoma, as well as advancing the development of its pipeline targeting multiple solid and li

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Aplastic Anemia - Pipeline Insight, 2019 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Aplastic Anemia - Pipeline Insight, 2019" drug pipelines report has been added to ResearchAndMarkets.com's offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Aplastic Anemia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, assoc

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 13:40

Cluster Headache Syndrome - Pipeline Insight, 2019 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cluster Headache Syndrome - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Cluster Headache Syndrome development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 13:34

TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products

GLASGOW, Scotland--(BUSINESS WIRE)--TC BioPharm (TCB), a developer of CAR-T immuno-oncology products, including Gamma Delta T (GDT) cell therapies, today announced it has completed formulation of its first allogeneic GDT cell banks. The T cell banks provide TCB with core technology to develop a deep portfolio of next-generation CAR-T products directed against a wide variety of different cancer types, both hematological and solid tumors. The project was supported by funding from the European Uni

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 12:55

Rationale and study design of the MyHEART study: A young adult hypertension self-management randomized controlled trial

Publication date: Available online 21 January 2019Source: Contemporary Clinical TrialsAuthor(s): Heather M. Johnson, Lisa Sullivan-Vedder, KyungMann Kim, Patrick E. McBride, Maureen A. Smith, Jamie N. LaMantia, Jennifer T. Fink, Megan R. Knutson Sinaise, Laura M. Zeller, Diane R. LauverAbstractYoung adults (18–39 year-olds) with hypertension have a higher lifetime risk for cardiovascular disease. However, less than 50% of young adults achieve hypertension control in the United States. Hypertension...

ScienceDirect Publication: Contemporary Clinical Trials

Tue Jan 22, 2019 13:13

EC approves Vertex's CF treatment Orkambi for children aged two to five years

The label extension has been granted to treat the most common form of CF based on data from a phase 3 open-label safety study in 60 patients. According The post EC approves Vertex's CF treatment Orkambi for children aged two to five years appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Tue Jan 22, 2019 12:25

Nash's NASH NP-160 shows repeated positive results in second pre-clinical study

In addition, a second compound, NP-135 was identified as an additional lead. Both NP-135 and NP-160 are one of a number of already approved compounds that Nash has The post Nash's NASH NP-160 shows repeated positive results in second pre-clinical study appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Tue Jan 22, 2019 12:25

Global Clinical Trials 2007-2018: Current Trends and Recent Advancements - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Clinical Trials - Current Trends and Recent Advancement" report has been added to ResearchAndMarkets.com's offering. "Global Clinical Trials Current Trends and Recent Advancement", provides an in-depth assessment of the current trends in the number of clinical trials globally, Top 10 therapy area, geography wise clinical trials, YOY clinical trials in top 10 therapy area. An overview of clinical guidelines reforms has also been provided to show how regulator

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 11:17

PredictImmune Confirms Canadian Patent Grant

CAMBRIDGE, England--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/IBD?src=hash" target="_blank"gt;#IBDlt;/agt;--PredictImmune confirm Canadian patent grant which covers PredictImmune's intellectual property relating to methods for predicting autoimmune disease

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 11:00

PCI announces further investment in infrastructure for packaging of controlled substances

PCI has extended onsite controlled substance storage at its US commercial packaging locations in Philadelphia, PA and Rockford, IL, and will undertake further expansions as demand increases for The post PCI announces further investment in infrastructure for packaging of controlled substances appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Tue Jan 22, 2019 12:25

Remove ads

Wren Therapeutics Completes £18 Million Series A Financing

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Wren Therapeutics ("Wren"), a biopharmaceutical company focused on drug discovery and development for protein misfolding diseases, today announces it has completed a Series A financing round. The company, formally founded in 2016, raised a total of £18 million from an international syndicate led by The Baupost Group with participation from LifeForce Capital and a number of high net worth individual investors. Protein molecules form the machinery that

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 09:30

EMMAC Life Sciences PLC: Acquisition of a Majority Interest in Medalchemy, a GMP Certified Laboratory, in Alicante Spain

LONDON--(BUSINESS WIRE)--EMMAC, the European independent medical cannabis company, is pleased to announce the acquisition of a majority interest in Medalchemy, a fully-licensed GMP certified laboratory in Alicante, Spain. Medalchemy, a technology-based manufacturing company located on the premises of the University of Alicante, has more than a decade of experience in the research, development and manufacture of active pharmaceutical ingredients (APIs) and has submitted license applications to i

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 09:00

Updated Analysis of Pivotal Study Reveals: Proactive, High Dosage of Venofer® Significantly Reduces Risk of Death or Major Cardiovascular Events in Haemodialysis Patients

ZURICH--(BUSINESS WIRE)--Re-analysis of pivotal study reveals: Proactive, High DOSAGE OF venofer®...

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 08:00

Ferring, Rebiotix and Karolinska Institutet Extend Collaboration to Research Next Generation of Microbiome Treatments

SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women's health and gastroenterology. The collaboration brings together specialist expertise from Karolinska Institutet in early stage research, Rebiotix Inc. (acquired by Ferring in 2018), a late-stage clinical microbiome company, and Ferring's therapeutic area and co

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 08:00

Proteus Digital Health Launches Digital Oncology Medicines to Improve Patient Outcomes

January 17, 2019 – REDWOOD CITY, Calif. and MINNEAPOLIS, Minn. – Proteus Digital Health®, Inc., Fairview Health Services, and University of Minnesota Health announced today that for the first time cancer patients are using digital...

Drugs.com - Clinical Trials

Thu Jan 17, 2019 22:01

Two Positive Phase III studies of Tafenoquine for the Radical Cure of Plasmodium vivax Malaria Published in The New England Journal of Medicine

London UK; Philadelphia US; Geneva Switzerland - January 16, 2019 -- GSK and Medicines for Malaria Venture (MMV) today announced the publication of positive results from two phase III studies of single-dose tafenoquine for the radical cure...

Drugs.com - Clinical Trials

Wed Jan 16, 2019 23:01

vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study

HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small...

Drugs.com - Clinical Trials

Wed Jan 16, 2019 22:01

Amgen Makes All Repatha (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at...

Drugs.com - Clinical Trials

Mon Jan 07, 2019 22:01

Gore führt GORE® TAG® Conformable Thoracic Stent Graft mit reduzierten Profilen für die Vermarktung in Europa ein

FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) meldete heute die Markteinführung reduzierter Profile für die am häufigsten verwendeten Durchmesser von GORE® TAG® Conformable Thoracic Stent Graft mit ACTIVE CONTROL System. Das reduzierte Profil ermöglicht es den Ärzten, bei Patienten mit kleineren Blutgefäßen eine thorakale endovaskuläre Aortenreparatur (TEVAR) durchzuführen, wenn der Zugang anspruchsvoll und die Aorta gewunden ist, um auf diese Weise die Einsatzmö

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 22:37

Gore lance sur le marché européen GORE® TAG®, une endoprothèse thoracique conformable à profils réduits

FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) a présenté aujourd'hui des profils réduits des diamètres les plus couramment utilisés de l'endoprothèse thoracique conformable implantable GORE® TAG® dotée du système ACTIVE CONTROL. La réduction du profil permet aux médecins de procéder à une procédure TEVAR (réparation endovasculaire des anévrismes de l'aorte thoracique) chez les patients dont les vaisseaux sont étroits et difficiles d'accès et l'anatomie aortique t

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 19:30

Riassunto: Gore lancia in Europa lo stent graft toracico conformabile GORE® TAG® con profili ridotti

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) ha oggi lanciato profili ridotti per i diametri più comunemente utilizzati dello stent graft toracico conformabile GORE® TAG® con sistema ACTIVE CONTROL. Il profilo ridotto consente al personale medico di eseguire trattamenti endovascolari dell'aorta toracica (TEVAR) nei pazienti con vasi sanguigni più piccoli, di difficile accesso e con anatomia aortica tortuosa, ampliando la disponibilità dello stent graft toracico di

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 16:18

Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 14:00

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. "Today's approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF," said Reshma K

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 11:00

Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 10:00

Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism

Promentis is developing SXC-2023 along with other compounds that engage System xc-, a central nervous system target addressing glutamatergic imbalance and oxidative stress, to treat trichotillomania and other The post Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Mon Jan 21, 2019 12:58

Kyn Therapeutics, Celgene partner on immuno-oncology therapies development

The collaboration will combine the immuno-oncology expertise and pipeline of Kyn Therapeutics with the capabilities of Celgene in development and commercialization of drugs in areas of high unmet The post Kyn Therapeutics, Celgene partner on immuno-oncology therapies development appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Mon Jan 21, 2019 09:02

Lilly's second immune-oncology candidate using Zymeworks' Azymetric platform to start clinical trials

In accordance with Zymeworks' 2014 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0 million for Lilly's submission of an IND application for The post Lilly's second immune-oncology candidate using Zymeworks' Azymetric platform to start clinical trials appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Mon Jan 21, 2019 12:58

SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine

TOKYO--(BUSINESS WIRE)--At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the "Company") resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group. (Hereinafter, the "Group" refers to two companies, SanBio Co., Ltd., and SanBio, Inc.) 1. Details of the Decision As part of its mission to introduce new therapeutic drugs for the central nervous system,

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 02:05

Design of a randomized trial testing a multi-level weight-control intervention to reduce obesity and related health conditions in low-income workers

Publication date: Available online 19 January 2019Source: Contemporary Clinical TrialsAuthor(s): Richard I. Stein, Jaime R. Strickland, Rachel G. Tabak, Ann Marie Dale, Graham A. Colditz, Bradley A. EvanoffAbstractWeight-control is a major public health focus for preventing multiple obesity-related health conditions. While clinic-based intensive lifestyle interventions are successful, low-socioeconomic-status (SES) populations, which have a higher burden of obesity, are difficult to reach; thus,...

ScienceDirect Publication: Contemporary Clinical Trials

Sun Jan 20, 2019 13:44